Misoprostol

證據等級: L5

預測適應症: 2 個

Misoprostol: From an Undocumented Original Indication to Amenorrhea

One-Sentence Summary

Misoprostol (DrugBank DB00929) is a prostaglandin E1 (PGE1) analog; its originally approved indication is not documented in this evidence pack (Blocking data gap). The TxGNN model predicts it may be effective for Amenorrhea, with a prediction score of 99.64%, but 0 clinical trials and only 7 loosely related publications currently support this direction — none of which studies misoprostol as a treatment for amenorrhea.

Quick Overview

Item	Content
Original Indication	Not documented in current evidence pack (drug not marketed; 0 regulatory licenses on file)
Predicted New Indication	Amenorrhea
TxGNN Prediction Score	99.64% (rank 9256)
Evidence Level	L4 (mechanism-only; no clinical trials, and available literature does not directly test the predicted indication)
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for misoprostol is not available in this evidence pack (data gap DG002). Based on known pharmacological class, misoprostol is a synthetic prostaglandin E1 (PGE1) analog whose primary clinical effects are inducing uterine contraction, ripening the cervix, and promoting expulsion of uterine contents — actions used across obstetric and gynecologic practice (e.g., labor induction, medical abortion, missed abortion management, postpartum hemorrhage).

This creates a directional mismatch with the predicted indication. Amenorrhea is the absence of menstruation, while misoprostol’s known pharmacology is oriented toward inducing uterine bleeding/expulsion. All 7 literature results returned for this pairing concern termination of pregnancy, missed/incomplete abortion, or abnormal uterine bleeding management — not treatment of amenorrhea as a condition. The more plausible explanation is that TxGNN’s knowledge graph places misoprostol near disease nodes that co-occur with “amenorrhea” in a pregnancy/reproductive-health context (e.g., as an inclusion criterion — “amenorrhea ≤35 days” defining early pregnancy in several trials), rather than a genuine treatment-efficacy signal.

A second, lower-ranked candidate (Atypical Coarctation of Aorta, score 99.30%, rank 15668) has a more coherent mechanistic story: PGE1 analogs (e.g., alprostadil) are used to maintain ductus arteriosus patency in duct-dependent congenital heart disease, and misoprostol’s PGE1 activity could theoretically extend to this. However, this candidate has zero supporting clinical trials or literature (Evidence Level L5) and is not discussed further below.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25394644	2015	RCT	Reproductive Sciences	Dose-ranging RCT (n=2500) of mifepristone (50–150mg) + misoprostol for termination of ultra-early pregnancy (amenorrhea ≤35 days); not a study of amenorrhea treatment
27678099	2017	RCT/Cohort	Reproductive Sciences	RCT (n=744) of low-dose mifepristone + self-administered misoprostol for ultra-early medical abortion, comparing hospital vs. self-administration
26001691	2015	Review	J Obstet Gynaecol Can	Review of endometrial ablation for abnormal uterine bleeding management; misoprostol context not central
26405260	2015	Cohort	Human Reproduction	Feasibility of low-dose mifepristone + misoprostol for unintended-pregnancy prevention administered before expected menstruation
29974571	2018	Cohort	J Obstet Gynaecol Res	Safety/efficacy of self-administered low-dose mifepristone + misoprostol for early medical abortion
1486304	1992	Cohort	BMJ	Medical management of missed abortion and anembryonic pregnancy
37113350	2023	Case report	Cureus	Case report of acute fatty liver of pregnancy presenting with amenorrhea as a symptom, not as a treatment target

Note: all seven results relate misoprostol to pregnancy termination or use “amenorrhea” only as a gestational-age descriptor. None evaluates misoprostol as a therapy for amenorrhea itself.

US Market Information

No regulatory licenses on file — misoprostol is currently recorded as 未上市 (not marketed) in this jurisdiction (0 total licenses).

Safety Considerations

Please refer to the package insert for safety information.

(TFDA labeling warnings/contraindications and DDI data are marked as Blocking data gaps (DG001) in this evidence pack and could not be retrieved.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted score is high, but the supporting evidence is mechanistically incoherent with the predicted indication — all available literature concerns pregnancy termination, not amenorrhea treatment — and no clinical trials exist for this drug-disease pair. This pattern is consistent with a spurious knowledge-graph association rather than a genuine repurposing signal, and a Blocking safety data gap (TFDA label data) prevents any safety pre-screening regardless.

To proceed, the following is needed:

TFDA label data (warnings, contraindications) to clear the Blocking gap (DG001)
Confirmed original approved indication and MOA for misoprostol (DG002)
Clinical/pharmacological clarification of what “amenorrhea” means in the TxGNN prediction context (induction of menses vs. treatment of amenorrhea as a condition) before further evidence search
If pursued, a targeted literature search specifically on misoprostol’s use in secondary amenorrhea etiologies, distinct from its use in pregnancy-termination protocols
No further action recommended on the secondary candidate (Atypical Coarctation of Aorta) absent any clinical or preclinical evidence (currently L5)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.